IPO opens with mixed signals

Symbiotec Pharmalab, an Indore-based pharmaceutical and biotechnology company, opened its ₹1,757-crore initial public offering on August 24. The issue, which closes on August 27, consists of a fresh issue of ₹150 crore and an offer for sale (OFS) of up to ₹1,607 crore. The price band is fixed at ₹938-988 per share, with a minimum bid of 15 shares, The Hindu Business Line reported. At the upper end of the band, the company is valued at around ₹6,350 crore.

The fresh issue proceeds will be used for debt repayment and general corporate purposes, with about ₹112.50 crore earmarked to prepay or repay borrowings, according to the company's red herring prospectus as reported by The Economic Times and Outlook Money.

The IPO saw muted demand on the first day. According to scanx.trade, the issue was subscribed 0.14 times overall, with QIBs at 0.00x, non-institutional investors (bHNI and sHNI) at 0.29x and 0.12x respectively, and retail at 0.20x. In contrast, Outlook Money reported about 70% subscription overall, citing QIBs at 35%, NIIs at 87%, and retail at 83%. The discrepancy in subscription figures could not be reconciled from available reports.

Anchor book and selling shareholders

Ahead of the IPO, Symbiotec raised ₹526.2 crore from anchor investors, allocating 53.25 lakh shares to 34 anchors at ₹988 per share. The anchor list includes Citigroup Global Markets, BNP Paribas, Singularity AMC (backed by Madhusudan Kela), Susquehanna Pacific, and TIMF Holdings, as reported by CNBC TV18. Domestic mutual funds such as ICICI Prudential, HDFC, Motilal Oswal, Mirae Asset, Tata, and Edelweiss picked up 31.98 lakh shares. Insurance companies Tata AIA Life, Bajaj Life, and Bharti AXA Life also participated.

Selling shareholders include promoter Satwani Holdings LLP (₹144 crore), investor Rosewood Investments (₹988 crore), and India Business Excellence Fund–III (₹475 crore), according to The Hindu Business Line. The prospectus filed on August 18 showed Rosewood and IBEF-III holding 34.78% and 24.16%, respectively, with promoters at 36.4%. However, CNBC TV18 reported a different pre-issue stake structure: promoters at 26.91%, Rosewood at 37.19%, and IBEF-III at 24.47%. The variation may stem from different calculation dates.

Company profile and growth plans

Symbiotec, founded in 2002, is an R&D-driven company operating across organic chemistry, biotechnology, and complex injectables. It claims a global leadership position in corticosteroid and steroidal-hormone APIs by volume, with market share figures varying by report: 38.2% and 23.8% respectively (The Hindu Business Line), or 36.2% and 44.2% (CNBC TV18). The company has two API plants with chemical synthesis capacity of 584.67 tonnes and fermentation capacity of 300 KL, plus additional facilities at Ujjain and Mhow, including a proposed 14 KL biologics fermentation unit, per The Hindu Business Line.

Nearly all revenue (96%) comes from steroid and hormone APIs, with about 67% of revenue from customers outside India, as reported by scanner.trade. The top five APIs contribute 62.27% of FY26 operating revenue, indicating concentration risk.

Management, including Chairman Anil Satwani and CFO Raghavender Ramachandran, has highlighted that the company's expansion into complex injectables and fermentation CDMO is nearing monetisation. They invested ₹800-850 crore in new capabilities, funded through accruals and borrowings. Satwani said, "The proof of concept is behind us. We are just waiting for these two big opportunities to get monetised in the coming years," as quoted by CNBC TV18.

The CFO noted that the core API business has an asset turnover of about 1.5 times, and the company could potentially double revenue without major additional capex. Adjusted core API ROCE improved from about 25% to about 30%, but consolidated returns lag until new assets contribute. Debt stood at around ₹380 crore as of March 31, 2026, expected to fall to about ₹230 crore post-IPO.

The company is also building a fermentation CDMO with 400 KL capacity (alongside 300 KL base), with take-or-pay contracts spanning 5–10 years, including alternate protein and fermentation APIs. Revenue from CDMO is expected late FY27, with significant ramp-up from FY28. It has commissioned 14 KL fermentation capacity for recombinant insulins and is awaiting DCGI approval to shift GLP-1 manufacturing to a recombinant method. An injectable facility with 20 million units capacity targets DCV formulations in FY27–28, as detailed in The Hindu Business Line's analysis.

Financial performance

For FY26, Symbiotec reported revenue of about ₹869 crore (up 15.6% from ₹752 crore) and profit of about ₹110 crore (up 13.6% from ₹97 crore), according to The Hindu Business Line. The Economic Times reported FY26 total income of ₹872.26 crore (+15.38%) and PAT of ₹109.90 crore (+13.54%). CNBC TV18 noted Q1 FY26 (June 2025 quarter) profit of ₹29.9 crore on revenue of ₹203.1 crore, while FY25 profit was ₹96.8 crore (down 3.3%). EBITDA margin averaged around 26% over the last three years, aided by about 80% backward integration from soybean phytosterol, per The Hindu Business Line. Satwani said there is zero manufacturing dependency on China, though some Chinese materials are sourced commercially.

Valuation and broker views

The IPO's valuation has drawn attention due to premium pricing. At the upper end of the band, the issue is valued at 57.8 times FY26 EPS (The Hindu Business Line). Based on diluted FY26 EPS, the P/E is 49.37x at the lower band and 52.00x at the upper band (The Economic Times). SBI Securities values the issue at a post-issue FY26 P/E of 54.6 times, calling it reasonable compared with peers; it has recommended Subscribe. KC Securities values it at 58.36 times, also with a Subscribe recommendation, as reported by CNBC TV18. Master Capital Services has also recommended Subscribe, citing the global API market's growth (USD 305.5 billion in 2025 to USD 424.6 billion by 2030, a 6.8% CAGR) and CDMO growth of 8.2% CAGR (The Economic Times).

The Hindu Business Line, in its investor analysis, noted the premium valuation but suggested that investors with a three- to five-year horizon could consider subscribing, given growth drivers in CDMO, injectables, and insulin/GLP-1. It also flagged a rights issue in December 2025 at ₹276 per share, largely subscribed by promoters, which is a discount to the IPO price.

Grey-market premium (GMP) varied: The Economic Times reported a GMP of ₹409 (41%), implying an estimated listing around ₹1,397, while Outlook Money reported GMP of ₹395, implying a listing near ₹1,383 (about 40% gain). These are unofficial and not verified.

Offer details

The IPO has a quota of 50% for QIBs, 15% for NIIs, and 35% for retail investors, with a ₹90 per share discount for eligible employees. The minimum investment for retail is ₹14,820 at the upper band; sHNI minimum is 210 shares (₹2,07,480) and bHNI minimum is 1,020 shares (₹10,07,760). Listing on BSE and NSE is tentatively September 1, with allotment expected August 28, according to The Economic Times. Book-running lead managers are JM Financial, Avendus Capital, Motilal Oswal Investment Advisors, and Nomura Financial Advisory; registrar is MUFG Intime.

Prior investors in Symbiotec include Actis, Franklin Templeton, and the late Rakesh Jhunjhunwala, as reported by CNBC TV18. Peers cited include Concord Biotech, Divi's Laboratories, Cohance Lifesciences, and Laurus Labs.